Novartis Ag

Novartis Pharmaceuticals Corporation

Juergen Sigg

Andrew Mark Bryant

Heinrich Buettgen

Marie Picci

Tudor Arvinte

Alexandra Glausch

Christophe Royer

Uwe Thomas Schote

Michael Billington

Rolf Löffler

Pamela De Moor

The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

Protein solution formulation containing high concentration of an anti-VEGF antibody

The present invention relates to a syringe, particularly to a small volume syringe such as a syringe suitable for ophthalmic injections.

Syringe

This invention provides a pharmaceutical composition in the form of a suspension comprising oxcarbazepine.

Suspension comprising oxcarbazepine

A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

Pharmaceutical products comprising bisphosphonates

This invention provides pharmaceutical compositions comprising TGF-&bgr;.

Growing community of inventors

Loerrach, Germany

Juergen Sigg